BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

 BioTime Acquires Asterias Biotherapeutics with Two of its Clinical Stage Cell Therapy Candidates

Shots:

  • Asterias to receive 0.71 share, for each of its share in BioTime making it an ownership of 16.2%. Biotime to get hold of all stock of Asterias along with two clinical stage candidates i.e. OPC1 & VAC2
  • The focus of the acquisition is to develop & commercialize novel therapies in fields of Immuno-oncology & Neurology
  • OPC1 is a therapy utilizing oligodendrocyte progenitor cells (OPCs), is currently evaluated in P-II for the treatment of Severe Spinal Cord Injury. VAC2 is an immunotherapy candidate, currently evaluated in P-I for the treatment of NSCLC in collaboration with Cancer Research UK

Click here to read full press release/ article | Ref: BioTime | Image: Commons Wikimedia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post